Thyrocare Technologies Limited Stock Price Today (NSE: THYROCARE)
Fundamental Score
Thyrocare Technologies Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Thyrocare Technologies Limited share price today is ₹541.30, down 0.58% on NSE/BSE as of 16 September 2026. Thyrocare Technologies Limited (THYROCARE) is a Mid-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹8.62K (Cr). The 52-week high for THYROCARE share price is ₹662.00 and the 52-week low is ₹342.55. At a P/E ratio of 31.67x, THYROCARE is currently trading below its industry average P/E of 42.23x. The company has a Return on Equity (ROE) of 28.80% and a debt-to-equity ratio of 0.00.
Thyrocare Technologies Limited Share Price Chart — NSE/BSE Historical Performance
Thyrocare Technologies Limited share price chart: -8.46% return over the past month. 52-week high ₹662.00, 52-week low ₹342.55.
Thyrocare Technologies Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹543.30 | ₹549.45 | ₹532.75 | ₹541.30 | 2.63L (Cr) | |
| ₹552.70 | ₹556.90 | ₹542.05 | ₹544.45 | 1.94L (Cr) | |
| ₹552.00 | ₹555.95 | ₹545.00 | ₹549.70 | 3.95L (Cr) | |
| ₹568.90 | ₹569.55 | ₹553.65 | ₹557.70 | 3.04L (Cr) | |
| ₹569.45 | ₹574.05 | ₹564.10 | ₹566.85 | 1.72L (Cr) | |
| ₹573.10 | ₹577.00 | ₹566.60 | ₹569.45 | 1.61L (Cr) | |
| ₹573.75 | ₹580.75 | ₹566.20 | ₹573.15 | 2.43L (Cr) | |
| ₹575.05 | ₹581.90 | ₹573.35 | ₹576.15 | 1.37L (Cr) | |
| ₹579.65 | ₹582.00 | ₹572.35 | ₹578.65 | 1.90L (Cr) | |
| ₹590.60 | ₹590.80 | ₹572.40 | ₹576.75 | 3.45L (Cr) |
Thyrocare Technologies Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹606.65 | ₹613.00 | ₹532.75 | ₹541.30 | -10.77% | |
| ₹583.00 | ₹662.00 | ₹563.10 | ₹604.50 | +3.69% | |
| ₹554.90 | ₹617.45 | ₹505.50 | ₹579.00 | +4.34% | |
| ₹528.75 | ₹578.25 | ₹495.00 | ₹549.30 | +3.89% | |
| ₹400.30 | ₹526.00 | ₹399.75 | ₹506.30 | +26.48% | |
| ₹359.55 | ₹418.00 | ₹352.90 | ₹400.30 | +11.33% | |
| ₹375.20 | ₹392.60 | ₹342.55 | ₹349.55 | -6.84% | |
| ₹404.95 | ₹425.05 | ₹376.50 | ₹393.65 | -2.79% | |
| ₹445.00 | ₹508.00 | ₹397.50 | ₹420.00 | -5.62% | |
| ₹489.00 | ₹492.00 | ₹408.10 | ₹445.70 | -8.85% | |
| ₹468.33 | ₹536.67 | ₹433.80 | ₹495.70 | +5.84% | |
| ₹386.63 | ₹491.33 | ₹376.67 | ₹465.77 | +20.47% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Thyrocare Technologies Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Thyrocare Technologies Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of THYROCARE across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (28.80%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (35.47%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (30.90%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 31.67 vs Industry: 42.23)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (34.06%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (24.34%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (76.53x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.77)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹606.08 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (60.93%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 26.36%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
3 factors identified
High Price-to-Book Ratio (5.25x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-13.66% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
High Share Pledging Risk (100.00%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Thyrocare Technologies Limited vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Thyrocare Technologies Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Thyrocare Technologies LimitedThyrocare Techn...Selected✓ THYROCARE • 539871 | 46.7/100 | ₹541.30₹541 | ₹8615.87₹8615.87 | 31.67Average 31.7 Average | 28.80%Excellent 28.80% Excellent | 35.47%Excellent 35.47% Excellent | 0.00Excellent 0.0 Excellent | 8.37%Good 8.37% Good | 10.88%Good 10.88% Good | 1.76% |
Dr. Lal Path Labs Ltd.Dr. Lal Path La... LALPATHLAB • 539524 | 57.7/100 | ₹1919.70₹1920 | ₹32174.17₹32174.17 | 46.28Average 46.3 Average | 21.57%Excellent 21.57% Excellent | 27.62%Excellent 27.62% Excellent | 0.00Excellent 0.0 Excellent | 11.60%Good 11.60% Good | 11.81%Good 11.81% Good | 0.81% |
Vijaya Diagnostic Centre LimitedVijaya Diagnost... VIJAYA • 543350 | 67.8/100 | ₹1498.90₹1499 | ₹15423.23₹15423.23 | 82.22Average 82.2 Average | 19.74%Good 19.74% Good | 21.32%Excellent 21.32% Excellent | 0.00Excellent 0.0 Excellent | 15.47%Excellent 15.47% Excellent | 16.66%Excellent 16.66% Excellent | 0.14% |
Metropolis Healthcare LimitedMetropolis Heal... METROPOLIS • 542650 | 57.9/100 | ₹602.10₹602 | ₹12483.64₹12483.64 | 25.79Average 25.8 Average | 13.36%Average 13.36% Average | 16.80%Good 16.80% Good | 0.01Excellent 0.0 Excellent | 0.74%Average 0.74% Average | 10.52%Good 10.52% Good | 0.35% |
Krsnaa Diagnostics LimitedKrsnaa Diagnost... KRSNAA • 543328 | 31.9/100 | ₹560.95₹561 | ₹1819.61₹1819.61 | 18.66Average 18.7 Average | 10.89%Average 10.89% Average | 13.05%Average 13.05% Average | 0.55Good 0.5 Good | -11.13%Poor -11.13% Poor | 11.75%Good 11.75% Good | 0.50% |
Suraksha Diagnostic LimitedSuraksha Diagno... SURAKSHA • 544293 | 56.2/100 | ₹335.65₹336 | ₹1748.10₹1748.10 | 48.79Average 48.8 Average | 14.11%Average 14.11% Average | 16.82%Good 16.82% Good | 0.01Excellent 0.0 Excellent | 31.68%Excellent 31.68% Excellent | 17.26%Excellent 17.26% Excellent | 0.00% |
One Global Service Provider LimitedOne Global Serv... ONEGLOBAL • 514330 | 82.2/100 | ₹540.40₹540 | ₹1178.25₹1178.25 | 16.95Average 16.9 Average | 65.27%Excellent 65.27% Excellent | 87.02%Excellent 87.02% Excellent | 0.00Excellent 0.0 Excellent | 97.21%Excellent 97.21% Excellent | 167.02%Excellent 167.02% Excellent | 0.00% |
3B Blackbio Dx Limited3B Blackbio Dx ... 3BBLACKBIO • 532067 | 60.3/100 | ₹1468.90₹1469 | ₹1079.13₹1079.13 | 18.42Average 18.4 Average | 19.77%Good 19.77% Good | 25.48%Excellent 25.48% Excellent | 0.01Excellent 0.0 Excellent | -12.44%Poor -12.44% Poor | -8.95%Poor -8.95% Poor | 0.31% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 39/100 | ₹301.45₹301 | ₹1035.54₹1035.54 | 539.34Average 539.3 Average | 0.29%Poor 0.29% Poor | -0.05%Poor -0.05% Poor | 0.04Excellent 0.0 Excellent | 16.91%Excellent 16.91% Excellent | 19.09%Excellent 19.09% Excellent | 0.00% |
49.4/100 | ₹218.40₹218 | ₹600.78₹600.78 | 20.55Average 20.6 Average | 19.92%Good 19.92% Good | 23.27%Excellent 23.27% Excellent | 0.31Excellent 0.3 Excellent | — — | — — | 0.00% | |
Choksi Imaging LtdChoksi Imaging ... CHOKSI • 526546 | 36.3/100 | ₹214.00₹214 | ₹122.00₹122.00 | 83.24Average 83.2 Average | 4.96%Poor 4.96% Poor | 18.96%Good 18.96% Good | 0.05Excellent 0.0 Excellent | 20.80%Excellent 20.80% Excellent | 12.36%Good 12.36% Good | 0.00% |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr. Lal Path Labs Ltd. share price32174.17 Cr
- Vijaya Diagnostic Centre Limited share price15423.23 Cr
- Metropolis Healthcare Limited share price12483.64 Cr
- Krsnaa Diagnostics Limited share price1819.61 Cr
- Suraksha Diagnostic Limited share price1748.10 Cr
Thyrocare Technologies Limited PE Ratio History
Historical price-to-earnings ratio for THYROCARE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹17.23 | ₹445.70 | 25.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Thyrocare Technologies Limited Dividend History
Annual cash dividends paid by THYROCARE — dividend yield 1.76%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹95.31 Cr |
| FY 2024 | ₹95.27 Cr |
| FY 2023 | ₹79.35 Cr |
| FY 2022 | ₹79.31 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Thyrocare Technologies Limited Quarterly Performance
Latest quarterly metrics for THYROCARE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
24.34%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
34.06%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.88%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
8.37%
Compounded annual net profit growth over 5 years
Thyrocare Technologies Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for THYROCARE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Thyrocare Technologies Limited Financial Statements
Annual income statement, balance sheet and cash flow for Thyrocare Technologies Limited (THYROCARE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Thyrocare Technologies Limited
About THYROCARE (Thyrocare Technologies Limited)
Thyrocare Technologies Ltd is a pioneering force in the Indian diagnostic industry, revolutionizing healthcare accessibility with its innovative and cost-effective testing solution...s. The company operates on a centralized processing laboratory model, enabling it to offer a comprehensive range of tests at affordable prices, making quality healthcare accessible to a wider population. Thyrocare focuses on preventive care, empowering individuals to proactively monitor their health and well-being through early detection and timely intervention. With a strong emphasis on automation and technology, Thyrocare has established itself as a reliable and efficient provider of diagnostic services, consistently delivering accurate and timely results. At the heart of Thyrocare's operations lies its Diagnostic Testing Services division, where the company meticulously processes a vast array of samples, ensuring precision and reliability in every test result. This segment is the backbone of Thyrocare, encompassing the sale of essential consumables required for sample collection, as well as strategic promotional activities designed to increase awareness and demand for pathology testing. Further expanding its diagnostic capabilities, Thyrocare's Imaging Services segment plays a crucial role in providing advanced imaging solutions. This division focuses on the sale of radio-pharmaceuticals and specialized consumables essential for accurate image reporting, contributing to comprehensive patient diagnosis and treatment planning. Beyond diagnostic testing and imaging, Thyrocare demonstrates its commitment to innovation through its "Others" segment. This division is dedicated to the sale of cutting-edge testing equipment and related consumables, supporting laboratories and healthcare facilities across India. By offering these essential resources, Thyrocare empowers healthcare providers to enhance their own diagnostic capabilities, ultimately contributing to the overall improvement of healthcare standards. Through its diverse offerings and unwavering focus on quality and affordability, Thyrocare Technologies Ltd continues to play a vital role in transforming the Indian healthcare landscape.
Company Details
Key Leadership
THYROCARE Share Price: Frequently Asked Questions
What is the current share price of Thyrocare Technologies Limited?
Thyrocare Technologies Limited (THYROCARE) trades at ₹541.30 on NSE and BSE. Market cap ₹8.62K (Cr). Educational data only.
What is the P/E ratio of Thyrocare Technologies Limited?
Thyrocare Technologies Limited has a P/E of 31.67x vs industry average 42.23x.
What is the Bull Run score for Thyrocare Technologies Limited?
Thyrocare Technologies Limited has a Bull Run score of 46.7/100 based on 25+ financial parameters.
Does Thyrocare Technologies Limited pay dividends?
Thyrocare Technologies Limited has a dividend yield of 1.76%. Past dividends don't guarantee future payments.
What is the ROE of Thyrocare Technologies Limited?
Thyrocare Technologies Limited has ROE of 28.80%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Thyrocare Technologies Limited?
Thyrocare Technologies Limited has debt-to-equity of 0.00.
Is Thyrocare Technologies Limited a good investment?
Bull Run gives Thyrocare Technologies Limited a score of 46.7/100. This is not investment advice — consult a SEBI-registered advisor.